Back

Effects of intravenous loop diuretic dose and delivery on congestion, natriuretic peptides, diuretic efficiency, and urinary sodium: findings from the DIUR-AHF Trial

12 May 2024 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Acute heart failure - pharmacotherapy 1 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Gaetano Ruocco

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
COR-1167, a new long-acting CRF2 receptor agonist, decreases congestion by improving cardiorenal function in a sheep model of worsening heart failure (WHF)
Doctor P. Janiak (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: the PARAGLIDE-HF Trial
Doctor A. Peters (Durham, US)
Abstract Slides Video
Presentation thumbnail
The impact of intrarenal venous doppler-guided diuretic management on hospital stay
Doctor M. Passos (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Mild-to-moderate chronic kidney disease predicts underutilisation of guideline-directed medical therapies in patients with acute heart failure
Associate Professor M. Polovina (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Response to up-titration of therapies in patients with new-onset heart failure with and without atrial fibrillation
Ms A. Zandijk (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure - pharmacotherapy 1

The Event

Event poster

Heart Failure 2024

12 May 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Different loop diuretic dosing and administration in acute Heart Failure (DIUR-AHF): effects on congestion renal function and outcome
thumbnail
Congress Presentation
DEA-HF: The heart failure diuresis efficacy comparison study
thumbnail
Congress Presentation
Thoracic fluid content as a marker of high intravenous diuretic requirements in patients hospitalized for heart failure decompensation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources